Company: Switzerland Omics GmbH/Sàrl (in formation) switzerlandomics.ch.
Product: Quant is the missing layer that makes genomics work. Interpretable, actionable, and accountable (see product page).
Founders: 12 years of PhD+ experience in applied genomics and statistical modelling. Backed by federal funding, national-scale clinical studies, and six years of development across UZH, EPFL, and ETH Zurich. Supported by senior advisors with academic, commercial, and regulatory expertise.
Stage: Pre-incorporation.
Grant requested: CHF 75,000 for legal setup and secure infrastructure.
The gap
Genomic sequencing is fast and affordable. But interpretation remains the bottleneck.
Clinical and pharmaceutical decisions depend on variant interpretation - yet current methods are fragmented, uncertain, and incomplete.
This is a 100-year-old problem requiring data and algorithms. Despite decades of theory, no complete solution existed until now.
Our solution
Quant (product page) is the first calibrated, genome-wide framework that turns raw variant evidence into interpretable, probabilistic Bayesian conclusions. It is a statistical engine and product suite. It consists of three interoperable tools:
- Quant database: pre-computed genome-wide priors.
- Quant scan: prepares and structures customer input.
- Quant calc: performs probabilistic inference and outputs credible intervals.
Capabilities:
- Genome and variant-level confidence outputs with full uncertainty accounting.
- Tailored priors for dominant, recessive, and X-linked models in disease.
- Integration of trusted databases including allele frequencies and clincal genetics.
- Validated on national-scale disease datasets.
Vision
Quant brings a generational shift in how genetic variation is understood.
- Our long-term goal is to license Quant across diagnostics, drug pipelines, and commercial genomics.
- A free tier is popularising our work through open-source, academically licensed software and datasets.
- We continue to build complementary products, including PanelAppRex AI (curated gene panels), Dante (AI-assisted clinical reporting), and related public/private databases to support scalable growth.
Traction
- Used in national rare disease diagnostics (Switzerland).
- Users of our documentation, codebase, and datasets.
- 2000+ online users.
- 300+ database users (i.e. downloads suitable for professionals).
Product maturity
- 6 years of development at UZH, EPFL, ETH Zurich.
- Peer-reviewed publications and cohort-scale validation.
- Ready-to-use tools: Quant db, Quant scan, Quant calc, QV database, PanelAppRex AI.
Use of funds
| Purpose | CHF |
|---|---|
| Legal registration (GmbH) | 3’000 |
| Legal setup and banking | 2’000 |
| Secure Swiss cloud servers | 10’000 |
| Secure off-site NAS 20TB | 5’000 |
| Launch of public Quant | 3’000 |
| Initial capital | 20’000 |
| Other (hardware, ops) | 23’500 |
| Partial salary | 8’500 |
| Total | 75’000 |
Covers full legal and operational setup and enables release of our full suite. Includes audit-compliant financials and secure data infrastructure planning.
Scientific and regulatory foundation
- Independent development with open-access, peer-reviewed validation.
- Prior art discovery confirming freedom to operate.
- Public documentation; auditable code, data, and financials.
- Regulation-ready for CH, EU, and US (EudraLex, ICH, FDA).
Impact
-
Research partnerships
Joint exploration of inference models, variant priors, or statistical architectures. -
Technology integration
Embed Quant, PanelAppRex AI, or other tools into internal pipelines with production-ready code, formats, and documentation. -
Co-development
Build custom datasets, metrics, or systems, grounded in shared standards, calibrated evidence, and mutual accountability.
Who it’s for
We collaborate with partners who build:
- AI models for genomic interpretation.
- Pharmacogenomics systems.
- Genome editing and design platforms.
- Large-scale population reference datasets.
- Clinical diagnostics and variant pipelines.
- Digital twin platforms for personalised simulation.
Request
We seek:
- CHF 75,000 seed grant for company registration and launch infrastructure.
- Collaboration with investors, institutions, and partners ready to scale robust genomic interpretation.
